Minerva Neurosciences (NERV)
(Delayed Data from NSDQ)
$2.44 USD
+0.01 (0.27%)
Updated Apr 26, 2024 03:37 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NERV 2.44 +0.01(0.27%)
Will NERV be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NERV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NERV
Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now
Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners
NERV: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Minerva Neurosciences (NERV) a New Buy Stock
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA
Biotech Stock Roundup: NERV, RLMD Down on Updates, MRNA, NVAX's News & More
Other News for NERV
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
BBAI, CTMX and STRC among mid-day movers
12 Health Care Stocks Moving In Tuesday's Intraday Session